Baricitinib for COVID-19: a suitable treatment? - Authors' reply.

Richardson, Peter J; Corbellino, Mario; Stebbing, Justin

Richardson, Peter J; Corbellino, Mario; Stebbing, Justin.

Richardson PJ; Benevolent AI, London, UK.
Corbellino M; III Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.
Stebbing J; Department of Surgery and Cancer, Imperial College, London W12 0NN, UK. Electronic address: j.stebbing@imperial.ac.uk.

Lancet Infect Dis ; 20(9): 1013-1014, 2020 09.

Article in English | MEDLINE | ID: covidwho-805940

Subject(s)

Antiviral Agents; Coronavirus Infections; Pandemics; Pneumonia, Viral; Anti-Inflammatory Agents; Azetidines; Betacoronavirus; COVID-19; Humans; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Pandemics Limits: Humans Language: English Journal: Lancet Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: S1473-3099(20)30270-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google